Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: A retrospective Japan Clear Cell Carcinoma Study

International Journal of Gynecological Cancer

Volumn 18, Issue 5, 2008, Pages 937-942

  Takano, M ^a   Sugiyama, T ^b   Yaegashi, N ^c   Sakuma, M ^c   Suzuki, M ^d   Saga, Y ^d   Kuzuya, K ^e   Kigawa, J ^f   Shimada, M ^f   Tsuda, H ^a   Moriya, T ^c   Yoshizaki, A ^b   Kita, T ^a   Kikuchi, Y ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f TOTTORI UNIVERSITY   (Japan)

Author keywords

Ovarian clear cell carcinoma; Recurrent; Refractory; Second line chemotherapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; MITOMYCIN C; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG TARGETING; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 51749104422     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01158.x     Document Type: Article

References (24)

1. Schiller W. Mesonephroma ovarii. Am J Cancer 1939 35 : 1 21.
2. Serov SF, Scully RE, Sobin LH. International histologic classification of tumors. In : Histologic typing of ovarian tumors, No. 9. Geneva, Switzerland : World Health Organization, 1973.
3. Goff BA, Sainz de la Cuesta R, Muntz HG et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996 60 : 412 7.
4. Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996 78 : 2157 63.
5. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian carcinoma cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993 49 : 250 4.
6. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experiences. J Clin Oncol 1991 9 : 1138 50.
7. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary. Cancer 2000 88 : 2584 9.
8. Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006 102 : 285 91.
9. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng J Med 1996 334 : 1 6.
10. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. Int J Gynecol Cancer 2003 13 : 735 40.
11. Enomoto T, Kuragaki C, Yamasaki M et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? [abstract] Proc Am Soc Clin Oncol 2003 22 : 447. Abstract 1797.
12. Ho CM, Huang YJ, Chen TC et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004 94 : 197 203.
13. Utsunomiya H, Akahira J, Tanno S et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 2006 16 : 52 6.
14. Ho CM, Chien TY, Shih BY, Huang SH. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 2003 88 : 394 9.
15. Takano M, Kikuchi Y, Yaegashi N et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006 94 : 1369 74.
16. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007 105 : 404 8.
17. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003 361 : 2099 106.
18. Kikuchi Y, Kita T, Takano M, Kudoh K, Yamamoto K. Treatment options in the management of ovarian cancer. Expert Opin Pharmacother 2005 6 : 743 54.
19. Takano M, Kikuchi Y, Yaegashi N et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 2006 94 : 1369 74.
20. Takano M, Kikuchi Y, Yaegashi N et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 2006 16 : 1301 6.
21. Takano M, Sugiyama T, Yaegashi N et al. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol 2007 12 : 256 60.
22. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 2007 105 : 404 8.
23. Sugiyama T, Yakushiji M, Nishida T et al. The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin. Cancer Lett 1996 105 : 203 9.
24. Nishida M, Tsunoda H, Ichikawa Y, Yoshikawa H. Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma. Int J Clin Oncol 2004 9 : 403 5.